Introduction
Recently, we demonstrated that nicotinamide phosphoribosyltransferase (NAMPT) is an essential enzyme mediator of G-CSF-triggered granulopoiesis seven members (SIRT1-7) of this family have been described in humans. Sirtuins possess either histone or protein deacetylase activity, and play a particularly important role in the response to certain types of stress and toxicity. Sirtuins are involved in lifespan extension, age-related disorders, obesity, heart disease, neurological function, and cancer 4 . SIRT1, one of the most extensively studied sirtuins, is known to deacetylate, and thereby inactivate, p53 and FOXO3a 5 . SIRT2, unlike SIRT1, is mostly found in the cytoplasm 2 and shows cell cycle-dependent intracellular localization, undergoing rapid nucleo-cytoplasmic shifts during G2/M cell-cycle progression. This observation together with the demonstration that overexpression of SIRT2 mediates a delay in cellular , FOXO transcription factors [10] [11] [12] , and p53 [13] [14] [15] .
The AKT pathway is frequently activated in AML [16] [17] [18] [19] [20] . Xu et al. reported elevated phosphorylation of AKT in 50-80% of purified blasts from AML patients 17 . Moreover, constitutive activation of AKT by phosphorylation was found in 50% of de novo AML samples analyzed in vitro after serum and cytokine starvation 19 . A study by Min et al. also reported that AKT/PKB was constitutively phosphorylated in a vast majority of AML cases 20 . However, the mechanisms leading to AKT activation in AML are not completely clear. NAMPT (visfatin) has recently been shown to induce AKT phosphorylation in endothelial cells and in cardiac fibroblasts 21, 22 .
AKT phosphorylates and thereby inhibits a serine-threonine kinase glycogen synthase kinase 3ß (GSK3ß) [23] [24] [25] . GSK3ß is a well known inhibitor of Wnt signaling.
GSK3ß targets the proto-oncogene ß-catenin and promotes its ubiquitination and proteasome-mediated degradation 25, 26 . Inactivation of GSK3ß leads to ß-catenin accumulation and redistribution to the nucleus 25, 26 . Nuclear ß-catenin interacts with LEF-1/TCFs transcription factors, which regulate cell survival and proliferation by activation of target genes c-myc, survivin and cyclin D1 27, 28 . ß-catenin induces proliferation and survival, but inhibits differentiation of hematopoietic stem cells (HSCs) [29] [30] [31] [32] [33] [34] [35] . Hyperactivated ß-catenin has been described in various hematological malignancies, such as acute and chronic myeloid leukemia, chronic lymphocytic leukemia, B-cell neoplasia, multiple myeloma 33, [36] [37] [38] [39] [40] [41] .
Here, we aimed to evaluate the involvement of NAMPT and SIRT2 in the aberrant proliferation and survival of leukemic cells, and to ascertain whether the AKT/GSK3ß/ß-catenin signaling pathway plays a role in mediating this process.
Design and Methods
Patients and control subjects. qRT-PCR. We isolated RNA using RNeasy Mini Kit, amplified cDNA with random hexamer primer and cDNA synthesis kit (Qiagen). We measured mRNA expression using SYBR green qPCR kit. Target gene mRNA expression was normalized to ß-actin and was represented as arbitrary units (AUs). Primer sequences are available on request.
Western blot analysis. We used: mouse anti-β-actin, rabbit anti-AKT, rabbit anti-phospho-AKT (Ser473) (193H12), rabbit anti-GSK-3β (27C10), rabbit anti-phospho-GSK-3β (Ser9) (5B3) (all from Cell Signaling Technology).
HRP-conjugated anti-mouse or anti-rabbit secondary antibodies (Santa Cruz Biotechnology) were used as appropriate. We obtained whole-cell lysates through direct 6 disruption in Laemmli loading buffer. We separated proteins by 10% SDS polyacryl-amide gel electrophoresis and probed the blots overnight at 4°C.
Detection of proteins and protein acetylation by in situ proximity ligation assay (DUOLINK). Endogenous SIRT2, NAMPT, phospho-Ser9-GSK-3β, and phospho-Ser33/37-ß-catenin proteins in the HL60 cell line, in CD34 + cells from healthy volunteers (n = 6), and in blasts from AML patents (n = 6) were detected using a proximity ligation assay (PLA) from the DUOLINK reagent series (Olink Bioscience, Uppsala, Sweden), as described in the manufacturer's protocol. Duolink allows to detected endogenous proteins or protein modifications trough a pair of specific oligonucleotide-conjugated antibodies. Individual proteins are visualized by fluorescent dots (red) of amplified oligonucleotides conjugated to antibodies, specific to protein/s of interest in the cell. Cytospin slides of cells (1X 10 4 cells/slide) have been done. Cells on cytospins were fixed in ice-cold methanol and permeabilized using 0.1% triton-X100.
Samples were blocked in 1× blocking stock (Olink Bioscience, Uppsala, Sweden) for 30 min at 37°C in a humidified chamber. All subsequent incubations were performed in a humidifying chamber maintained at 37 °C. We used rabbit anti-SIRT2, goat anti-NAMPT/PBEF (SC-46440) (both from Santa Cruz Biotechnology), rabbit anti-phospho-GSK-3β (Ser9) (5B3), rabbit anti-phospho-ß-catenin (Ser33/37) (all from Cell Signaling Technology). Acetylation of AKT protein was analysed by DUOLINK using rabbit anti-AKT (9272) (Fig. 1a) . As a first step toward assessment of the role of NAMPT and sirtuins in AML, we measured the levels of NAMPT, SIRT1, and SIRT2 in blasts of AML patients. We found upregulation of NAMPT mRNA and protein levels in AML blasts (n = 11) compared to CD34 + hematopoietic cells from healthy individuals (n = 6) ( Fig. 1b, e) . We also detected significantly elevated levels of SIRT2 mRNA and protein expression in AML blasts ( Fig.   1c, f) . In contrast, SIRT1 mRNA levels were unchanged or even slightly diminished in AML blasts compared to cells from healthy individuals (Fig. 1d) .
Moreover, in a separate set of experiments using microarrays to analyze mRNA expression levels in patients, we identified significantly elevated levels of SIRT2 mRNA in a high-risk (HR) group of AML patients (n = 33) compared to a standard-risk (SR) group (n = 18) (Fig. 1g , Suppl. Table 1 ). Interestingly, we found significantly diminished levels of SIRT2 in CBF-AML samples (with t(8;21) and inv (16) 
Inhibition of NAMPT or SIRT2 inactivates AKT and activates GSK-3ß.
We next analyzed the mechanism underlying the anti-proliferative and pro-apoptotic effects of FK866 and AC93253 using the HL60 cell line. The phosphoinositol 3-kinase (PI3K)/AKT pathway is frequently activated in AML [16] [17] [18] [19] [20] , and it is known that NAMPT induces AKT phosphorylation 21, 22 . We did not detect any changes in the levels of phospho-PI3K p85 (Tyr 458) or expression of total PI3K p85 protein in HL-60 cells treated with FK866 or AC93253 compared to DMSO-treated control cells (Suppl. Fig. 1 ).
However, after inhibition of NAMPT or SIRT2 with FK866 or AC93253, respectively, we did find reduced phospho-AKT levels (Fig. 5a ). SIRT2 is a protein deacetylase.
Therefore, we next analyzed whether NAMPT or SIRT2 inhibition may lead to reduced AKT phosphorylation by acetylation of AKT protein. Indeed, we found significantly elevated levels of acetylated AKT after inhibition of NAMPT or SIRT2, in comparison to control DMSO treated cells (Fig. 5b) . Because AKT phosphorylates GSK3ß on Ser 9 and inhibits GSK3ß activity (Fig. 5c) , we assessed the levels of phospho-GSK3ß in HL60 cells treated with FK866 or AC93253. We detected a dramatic reduction in the levels of phospho-GSK3ß, but not of total GSK3ß proteins, in cells exposed to FK866 or AC93253 compared to DMSO-treated controls (Fig. 5d ). An in situ proximity ligation assay (PLA) also revealed severely reduced levels of phospho-GSK3ß in HL60 cells after inhibition of NAMPT or SIRT2 (Fig. 5e ).
Inhibition of NAMPT or SIRT2 is associated with ß-catenin inhibition.
GSK3ß is a potent inhibitor of ß-catenin. The dephosphorylated (active) form of GSK3ß promotes ß-catenin degradation by phosphorylating ß-catenin on Ser33/37 25, 26 .
Consistent with the known activation of ß-catenin in AML blasts 33, 40, 41 , we found that the levels of nuclear ß-catenin were elevated in blasts of a selected AML patient (Fig. 6a) .
Therefore, we analyzed whether NAMPT or SIRT2 inhibition resulted in increased phosphorylation of ß-catenin. Indeed, we found elevated levels of inactivated phospho-ß-catenin in HL60 cells treated with FK866 or AC93253, and in primary blasts of three AML M2 patients treated with AC93253 compared to DMSO-treated control cells (Fig. 6b,c) . Moreover, mRNA expression levels of the ß-catenin target genes, LEF-1, survivin, cyclin D1 and c-Myc were also significantly reduced in AML blasts treated with either FK866 or AC93253 compared to DMSO-treated control cells (Fig. 6d) . Taken together, these results indicate that inhibition of NAMPT or SIRT2 results in the deactivation of AKT and activation of GSK-3ß via de-phosphorylation, leading to inactivation of ß-catenin through phosphorylation.
Discussion
Sirtuins represent a complex family of proteins (SIRT1-7) that show homology to the In our study, we demonstrated that SIRT2 expression was significantly upregulated in leukemic cells from patients suffering from AML, whereas SIRT1 levels were unchanged or even diminished. Moreover, we found significantly elevated levels of SIRT2 in patients with HR AML, in comparison to SR group, which demonstrates the involvement of SIRT2 in the proliferation of leukemic blasts and in the resistance against chemotherapy.
Because the effects of SIRT2 inhibition were similar to those of NAMPT inhibition, we hypothesize that overexpression of SIRT2 in AML is caused by its NAMPT-dependent activation. Recently, we demonstrated that G-CSF, a cytokine that is also known to stimulate myeloid leukemic cells, is a potent inducer of NAMPT expression. We further showed that NAMPT subsequently leads to a substantial activation of SIRT1 1 . The data showing dramatically elevated levels of NAMPT in AML blasts with subsequent hyperactivation of SIRT2 support our theory about dose-dependent effects of NAMPT in hematopoiesis: NAMPT is essential for proper myeloid differentiation, but hyperactivation of NAMPT may lead to leukemogenic transformation. Indeed, previously we showed that NAMPT and SIRT1 induce myeloid differentiation 1 , but it remains to be investigated if SIRT2 could also be involved in myeloid differentiation, redundantly to SIRT1. Our demonstration that both FK866, a specific inhibitor of NAMPT, and AC93253, a specific SIRT2 inhibitor, decreased proliferation of de novo AML cells and AML cell lines (HL60 and NB4), inducing apoptosis of these cells, provides support for our previous observation that NAMPT is responsible, at least in part, for the increase in SIRT2 levels. Moreover, inhibition of NAMPT led to diminished SIRT2 activity. These data confirm our hypothesis that NAMPT induces aberrant proliferation of leukemic cells through activation of SIRT2 and that NAMPT and SIRT2 play crucial roles in the increased and sustained proliferation of myeloid leukemic cells. It has been shown that AC93253 also inhibits SIRT1, albeit at significantly higher concentrations, as we used in our study 43 . Therefore, from the presented set of experiments we could not exclude at least partial effects of SIRT1 inhibition on cell proliferation and survival of AML cells. Interestingly, we demonstrated that inhibition of SIRT2 or NAMPT resulted in dephosphorylation/activation of GSK3ß and subsequent phosphorylation/deactivation of ß-catenin, which is the first step in ß-catenin degradation. Because inhibition of either SIRT2 or NAMPT induced dephosphorylation/inactivation of AKT, this process is most likely AKT-dependent.
On the basis of our findings, we propose that elevated levels of NAMPT are involved in aberrant proliferation of myeloid leukemic cells via activation of SIRT2 and the proto-oncogene, ß-catenin (Fig. 6e) . The fact that inhibition of NAMPT or SIRT2 had no effect on the proliferation of CD34 + hematopoietic progenitor cells from healthy individuals establishes these proteins as promising therapeutic targets for the treatment of leukemia. 
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